# Integer Holdings Corp: Form 10-Q for the period ended Oct 3, 2014

- Company: [Integer Holdings Corp](/companies/itgr.md) (CIK 1114483)
- Form: 10-Q
- Filed: 2014-11-12
- Accepted by EDGAR: Nov 12, 2014, 11:39 ET
- Period: 2014-10-03
- Accession: 0001114483-14-000032
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1114483/000111448314000032/gb-20141003x10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1114483/000111448314000032/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2014-10-03.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2014-07-05 to 2014-10-03 | $171.7m | us-gaap:SalesRevenueNet |
| Revenue | 9 months, 2014-01-04 to 2014-10-03 | $518.1m | us-gaap:SalesRevenueNet |
| Cost of revenue | 3 months, 2014-07-05 to 2014-10-03 | $113.6m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 9 months, 2014-01-04 to 2014-10-03 | $343.9m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months, 2014-07-05 to 2014-10-03 | $58.1m | us-gaap:GrossProfit |
| Gross profit | 9 months, 2014-01-04 to 2014-10-03 | $174.2m | us-gaap:GrossProfit |
| Selling, general and administrative | 3 months, 2014-07-05 to 2014-10-03 | $22.1m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months, 2014-01-04 to 2014-10-03 | $65.8m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2014-07-05 to 2014-10-03 | $16.2m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2014-01-04 to 2014-10-03 | $58.2m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2014-07-05 to 2014-10-03 | $1.1m | us-gaap:InterestExpense |
| Interest expense | 9 months, 2014-01-04 to 2014-10-03 | $3.2m | us-gaap:InterestExpense |
| Income tax | 3 months, 2014-07-05 to 2014-10-03 | $4.9m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2014-01-04 to 2014-10-03 | $17.8m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2014-07-05 to 2014-10-03 | $14.0m | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2014-01-04 to 2014-10-03 | $41.3m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2014-07-05 to 2014-10-03 | $0.54 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2014-01-04 to 2014-10-03 | $1.60 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2014-07-05 to 2014-10-03 | $0.56 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2014-01-04 to 2014-10-03 | $1.67 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2014-07-05 to 2014-10-03 | 25,923,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2014-01-04 to 2014-10-03 | 25,850,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2014-01-04 to 2014-10-03 | $54.7m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2014-01-04 to 2014-10-03 | $16.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2014-10-03 | $61.6m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2014-10-03 | $326.9m | us-gaap:AssetsCurrent |
| Total assets | at 2014-10-03 | $931.3m | us-gaap:Assets |
| Current liabilities | at 2014-10-03 | $90.0m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2014-10-03 | $334.2m | us-gaap:Liabilities |
| Long-term debt | at 2014-10-03 | $190.0m | us-gaap:LongTermDebtNoncurrent |
| Shareholders' equity | at 2014-10-03 | $597.1m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 58,472 characters.

### Our Business

In connection with the realignment of our operating structure in 2013 to optimize profitable growth, which included changing our management and reporting structure, we reevaluated our operating and reporting segments. Beginning in the fourth quarter of 2013, we have two reportable segments: Greatbatch Medical and QiG Group (“QiG”). As required, prior year amounts have been reclassified in order to conform them to the current year presentation. Greatbatch Medical designs and manufactures products where Greatbatch either owns the intellectual property or has unique manufacturing and assembly expertise. The financial results of Greatbatch Medical include the former Implantable Medical and Electrochem Solutions (“Electrochem”) segments, excluding QiG. These products include medical devices and components for the cardiac, neuromodulation, orthopaedic, portable medical, vascular, and energy, military and environmental (“EME”) markets. The Greatbatch Medical segment also offers value-added assembly and design engineering services for medical devices that utilize its component products.

QiG focuses on developing medical device systems for some of healthcare’s most pressing challenges and reflects Greatbatch’s strategic evolution of its product offerings in order to raise the growth and profitability profile of the Company. Through the research and development professionals in QiG, the Company is now investing in three areas — new medical device systems commercialization, collaborative programs with original equipment manufacturers (“OEM”) customers, and strategic equity positions in start-up companies — to grow a diversified and distinctive portfolio. The medical device systems developed by QiG will be manufactured by Greatbatch Medical. For the 2014 and 2013 periods, no revenue earned by QiG was manufactured by Greatbatch Medical.

### Our Acquisition

On August 12, 2014, we purchased all of the outstanding common stock of Centro de Construcción de Cardioestimuladores del Uruguay (“CCC”), headquartered in Montevideo, Uruguay. CCC is an active implantable neuromodulation medical device systems developer and manufacturer that produces a range of medical devices including implantable pulse generators, programmer systems, battery chargers, patient wands and leads. This acquisition allows us to more broadly partner with medical device companies, complements our core discrete technology offerings and enhances our medical device innovation efforts. The operating results of CCC have been included in our QiG segment from the date of acquisition. For the three and nine months ended October 3, 2014, CCC added approximately $1.6 million to the Company’s revenue and increased the Company’s net income by $0.4 million. The aggregate purchase price of $19.6 million was funded with cash on hand and was allocated to net tangible assets of $5.2 million, amortizing intangible assets of $6.1 million and $8.3 million to goodwill.

### Our Customers

The nature and extent of our selling relationships with each of our customers is different in terms of breadth of products purchased, product volumes, length of contractual commitment, ordering patterns, inventory management and selling prices. Our Greatbatch Medical customers include large multi-national OEMs, such as Biotronik, Boston Scientific, Halliburton, Johnson & Johnson, Medtronic, Philips Healthcare, Smith & Nephew, Sorin Group, St. Jude Medical, Stryker, and Zimmer. For the nine months ended October 3, 2014, Johnson & Johnson, Medtronic and St. Jude Medical collectively accounted for 47% of our total sales.

QiG customers include numerous scientists, hospitals and universities throughout the world who perform research for the neuroscience and clinical markets. Additionally, with the acquisition of CCC, QiG customers also include various research companies and institutes and early stage medical device companies.

### Financial Overview

On an organic constant currency basis, third quarter 2014 sales increased 1% in comparison to the prior year period. However, for the first nine months of 2014, sales increased 5% on an organic constant currency basis, which is consistent with our strategic goal of 5% organic constant currency growth. Sales for the third quarter of 2014 include $1.6 million from the acquisition of CCC, which was acquired in August 2014. Foreign currency exchange rate fluctuations did not have a material impact on sales for the third quarter of 2014, but increased sales by approximately $2.5 million for the first nine months of 2014 in comparison to the prior year period. We expect foreign currency exchange rates to be a headwind on sales growth for the remainder of 2014 due to the strengthening U.S. dollar versus the Euro. During the third quarter and for the first nine months of 2014, we experienced double digit growth in sales from our orthopaedic and vascular product lines as we continue to realize the benefits of our increased sales force productivity, marketing efforts and market growth. For the third quarter of 2014, our cardiac and neuromodulation sales remained consistent with the prior year, as new sales opportunities with existing customers offset the end of life impact for two legacy products. For the first nine months of 2014, cardiac and neuromodulation sales increased 5% due to the timing of customer product launches and inventory replenishments. As expected, our portable medical sales decreased 11% and 12% for the 2014 third quarter and year-to-date periods, respectively, as we are refocusing our product line offerings in the portable medical space to products that have higher profitability and correspondingly have discontinued or reduced volumes in certain of our lower margin products.

We prepare our condensed consolidated financial statements in accordance with generally accepted accounting principles in the United States of America (“GAAP”). Additionally, we consistently report and discuss in our quarterly earnings releases and investor presentations adjusted operating income and margin, adjusted net income, adjusted earnings per diluted share and organic constant currency growth rates. These adjusted amounts, other than organic constant currency growth rates, consist of GAAP amounts excluding the following adjustments to the extent they occur during the period: (i) acquisition-related charges, (ii) facility consolidation, optimization, manufacturing transfer and system integration charges, (iii) asset write-down and disposition charges, (iv) severance charges in connection with corporate realignments or a reduction in force, (v) litigation charges and gains, (vi) the impact of certain non-cash charges to interest expense, (vii) unusual or infrequently occurring items, (viii) for 2013, certain R&D expenditures (such as medical device design verification (“DVT”) expenses in connection with developing our neuromodulation platform), (ix) gain/loss on the sale of investments, (x) the income tax (benefit) related to these adjustments and (xi) certain tax items related to the Federal R&D Tax Credit which are outside the normal benefit received. To calculate organic constant currency growth rates, which excludes the impact of changes in foreign currency exchange rates, as well as the impact of any acquisitions or divestitures of product lines on sales growth rates, we convert current period sales from local currency to U.S. dollars using the previous periods' foreign currency exchange rates and exclude the amount of sales acquired/divested during the period from the current/previous period amounts, respectively.

We believe that reporting these amounts provides important supplemental information to our investors and creditors seeking to understand the financial and business trends impacting our financial condition and results of operations. Additionally, certain performance-based compensation incentives provided to our executives are determined utilizing these adjusted amounts.

A reconciliation of GAAP operating income (loss) to adjusted amounts is as follows (dollars in thousands):

|  | Three Months Ended Greatbatch Medical Oct. 3, 2014 | Sept. 27, 2013 | QiG Oct. 3, 2014 | Sept. 27, 2013 | Unallocated Oct. 3, 2014 | Sept. 27, 2013 | Total Oct. 3, 2014 | Sept. 27, 2013 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Sales | $169,225 | $167,052 | $2,474 | $678 | $— | $— | $171,699 | $167,730 |
| Operating income (loss) as reported | $31,121 | $28,236 | $(6,796) | $(6,946) | $(8,142) | $(4,288) | $16,183 | $17,002 |
| Adjustments: |  |  |  |  |  |  |  |  |
| Inventory step-up amortization (COS) | — | — | 87 | — | — | — | 87 | — |
| Medical device DVT expenses (RD&E)(a) | — | — | — | 1,510 | — | — | — | 1,510 |
| Consolidation and optimization costs | 3,116 | 3,286 | 613 | 80 | 23 | 199 | 3,752 | 3,565 |
| Acquisition and integration (income) expenses | 49 | 18 | (128) | (540) | 212 | — | 133 | (522) |
| Asset dispositions, severance and other | 276 | 31 | 606 | 426 | 1,409 | — | 2,291 | 457 |
| Adjusted operating income (loss) | $34,562 | $31,571 | $(5,618) | $(5,470) | $(6,498) | $(4,089) | $22,446 | $22,012 |
| Adjusted operating margin | 20.4% | 18.9% | N/A | N/A | N/A | N/A | 13.1% | 13.1% |

- 30 -

|  | Nine Months Ended Greatbatch Medical Oct. 3, 2014 | Sept. 27, 2013 | QiG Oct. 3, 2014 | Sept. 27, 2013 | Unallocated Oct. 3, 2014 | Sept. 27, 2013 | Total Oct. 3, 2014 | Sept. 27, 2013 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Sales | $514,036 | $485,168 | $4,025 | $2,158 | $— | $— | $518,061 | $487,326 |
| Operating income (loss) as reported | $98,688 | $84,596 | $(18,882) | $(21,679) | $(21,560) | $(14,441) | $58,246 | $48,476 |
| Adjustments: |  |  |  |  |  |  |  |  |
| Inventory step-up amortization (COS) | — | — | 87 | — | — | — | 87 | — |
| Medical device DVT expenses (RD&E)(a) |  | — |  | 4,479 |  | — | — | 4,479 |
| Consolidation and optimization costs | 6,036 | 9,237 | 679 | 80 | 255 | 1,018 | 6,970 | 10,335 |
| Acquisition and integration (income) expenses | 79 | 89 | (731) | (430) | 404 | 1 | (248) | (340) |
| Asset dispositions, severance and other | 269 | 139 | 606 | 426 | 2,626 | — | 3,501 | 565 |
| Adjusted operating income (loss) | $105,072 | $94,061 | $(18,241) | $(17,124) | $(18,275) | $(13,422) | $68,556 | $63,515 |
| Adjusted operating margin | 20.4% | 19.4% | N/A | N/A | N/A | N/A | 13.2% | 13.0% |

(a) As a result of our premarket approval (“PMA”) submission to the United States Food & Drug Administration (“FDA”) for Algovita, our Spinal Cord Stimulation (“SCS”) system to treat chronic pain of the trunk and limbs, in December 2013, we no longer exclude DVT costs associated with this system from adjusted operating income and adjusted diluted EPS. DVT costs incurred in connection with the development of this system during the three and nine month periods ended October 3, 2014 were $284 thousand and $1.4 million, respectively.

GAAP operating income for the third quarter decreased 5% and increased 20% for the first nine months of 2014 in comparison to the prior year. Adjusted operating income, which excludes net other operating expenses, inventory step-up amortization and DVT costs (for the 2013 period only), increased 2% and 8% for the third quarter and first nine months of 2014, respectively. These GAAP and adjusted operating income variances are primarily due to the following:

#### Third Quarter 2014

- A 4% increase in gross profit driven primarily by higher sales volumes and the CCC acquisition. Additionally, in comparison to the prior year third quarter, gross profit as a percentage of sales increased 50 basis points due to production efficiencies and higher margin sales mix, which more than offset the impact of contractual price concessions granted to our customers in exchange for long-term agreements;
- A 3% increase in selling, general, and administrative (“SG&A”) expenses primarily attributable to the CCC acquisition. This quarter over quarter increase also reflects the impact of the investments we have made in sales and marketing, as well as higher legal fees, which includes intellectual property related costs. The impact of these increases was almost entirely offset by our various consolidation initiatives, including our operating unit realignment in the second quarter of 2013;
- A 1% decrease in our net research, development and engineering (“RD&E”) costs as lower DVT costs incurred in connection with the development of Algovita, was partially offset by higher performance-based compensation in connection with the achievement of certain Algovita milestones, and a higher rate of spend on the other QiG medical device projects. Note that for 2013, we excluded DVT costs from adjusted operating income; and
- The decrease in GAAP operating income for the third quarter of 2014 in comparison to 2013 was also due to a higher level of net other operating expenses incurred in connection with our 2014 investments in capacity and capabilities, offset by lower costs incurred in connection with our orthopaedic facility optimization initiative and 2013 operating unit realignment. See "Cost Savings and Consolidation Initiatives" section for further description of these projects.

#### First Nine Months 2014

- An 8% increase in gross profit driven primarily by higher sales volumes. Additionally, in comparison to the first nine months of the prior year, gross profit as a percentage of sales increased 40 basis points due to production efficiencies and higher margin sales mix, which more than offset the impact of contractual price concessions granted to our customers in exchange for long-term agreements;
- A 3% increase in SG&A expenses primarily attributable to our increased investments in sales and marketing and increased legal fees, which includes intellectual property related costs, partially offset by cost savings realized in connection with our operating unit realignment in the second quarter of 2013; and
- A 3% increase in our net RD&E costs primarily attributable to lower customer cost reimbursements due to the timing of achievement of milestones on various projects. Additionally, lower DVT costs were offset by higher costs incurred in connection with the development of our next generation cardiac products (i.e. batteries, capacitors, filtered feedthroughs) and performance-based compensation in connection with the achievement of certain Algovita milestones. Note that for 2013, we excluded DVT costs from adjusted operating income.

A reconciliation of GAAP net income and diluted EPS to adjusted amounts is as follows (in thousands, except per share amounts):

|  | Three Months Ended October 3, 2014 Net Income | Per Diluted Share | September 27, 2013 Net Income | Per Diluted Share | Nine Months Ended October 3, 2014 Net Income | Per Diluted Share | September 27, 2013 Net Income | Per Diluted Share |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Net income as reported | $14,012 | $0.54 | $11,071 | $0.44 | $41,282 | $1.60 | $26,486 | $1.06 |
| Adjustments: |  |  |  |  |  |  |  |  |
| Inventory step-up amortization (COS)(a) | 57 | — | — | — | 57 | — | — | — |
| Medical device DVT expenses (RD&E)(a) | — | — | 981 | 0.04 | — | — | 2,911 | 0.12 |
| Consolidation and optimization costs(a) | 2,508 | 0.10 | 2,453 | 0.10 | 3,763 | 0.15 | 7,749 | 0.31 |
| Acquisition and integration (income) expenses(a) | 87 | — | (339) | (0.01) | (161) | (0.01) | (221) | (0.01) |
| Asset dispositions, severance and other(a) | 1,489 | 0.06 | 298 | 0.01 | 2,276 | 0.09 | 389 | 0.02 |
| (Gain) loss on cost and equity method investments, net(a)(b) | (2,044) | (0.08) | 10 | — | (2,551) | (0.10) | 408 | 0.02 |
| CSN conversion option discount and deferred fee accelerated amortization(a)(c) | — | — | 101 | — | — | — | 3,007 | 0.12 |
| R&D Tax Credit(d) | 400 | 0.02 | (100) | — | 1,200 | 0.05 | (1,600) | (0.06) |
| Adjusted net income and diluted EPS(e) | $16,509 | $0.64 | $14,475 | $0.57 | $45,866 | $1.77 | $39,129 | $1.56 |
| Adjusted diluted weighted average shares | 25,923 |  | 25,188 |  | 25,850 |  | 25,017 |  |

(a) Net of tax amounts computed using a 35% tax rate for all non-Swiss items and a 0% tax rate for Swiss items for both the 2014 and 2013 periods.

(b) Pre-tax amount is a gain of $3.1 million and $3.9 million for the 2014 quarter and year-to-date periods, respectively, and a loss of $16 thousand and $628 thousand for the 2013 quarter and year-to-date periods, respectively.

(c) Pre-tax amount is $156 thousand and $4.6 million for the 2013 quarter and year-to-date periods, respectively.

(d) The Federal R&D tax credit has not yet been extended for 2014. The 2014 amount assumes that the tax credit will be enacted for the full year 2014. The 2013 amount relates to the 2012 portion of the R&D tax credit which was reinstated in the first quarter of 2013 retroactive to the beginning of 2012. As required, the impact of the R&D tax credit relating to 2012 was recognized in the first quarter of 2013.

(e) The per share data in this table has been rounded to the nearest $0.01 and therefore may not sum to the total.

GAAP and adjusted diluted EPS for the third quarter of 2014 were $0.54 and $0.64, respectively, compared to $0.44 and $0.57, respectively, for the third quarter 2013. For the first nine months of 2014, GAAP and adjusted diluted EPS were $1.60 and $1.77, respectively, compared to $1.06 and $1.56 per share, respectively, for the same period of 2013. These variances were primarily due to the same factors impacting GAAP and adjusted operating income discussed above, as well as the following:

- Lower interest expense as a result of lower interest rates paid on our long-term debt due to the repayment of our convertible subordinated debt with availability under our Credit Facility in the first quarter of 2013;
- During the third quarter of 2014, we sold one of our cost method investments, which resulted in a pre-tax gain of $3.2 million. Additionally during the third quarter of 2014, we recognized $0.7 million of foreign currency exchange gains due to the strengthening of the U.S. dollar relative to the Euro. For the year-to-date period, we recognized $3.9 million of income realized on our cost and equity method investments and $0.4 million of income related to foreign currency exchange rate fluctuations. Gains/losses on our cost and equity method investments are excluded from adjusted amounts.
- The changes in the GAAP effective tax rate between the 2014 third quarter and year-to-date periods in comparison to the same periods of 2013 were primarily due to the timing of the Federal R&D tax credit, as well as the 2014 periods having higher income in lower tax rate jurisdictions. The Federal R&D tax credit expired at the end of 2013 and has not yet been extended for 2014. Additionally, we recognized the full year 2012 R&D tax credit in the first quarter of 2013 as the credit was reinstated, retroactive to the beginning of 2012, in that period.
- An increase in weighted average diluted shares outstanding for the third quarter and first nine months of 2014 versus the same periods of 2013 as a result of the increase in our stock price during those respective periods. This increase reduced the 2014 third quarter diluted EPS by $0.02 and $0.05 per share on both a GAAP and adjusted basis and $0.05 and $0.06 per share on a GAAP and adjusted basis, respectively, for the 2014 year-to-date period.

### Financial Guidance

Based upon our results for the first three quarters of the year, the addition of CCC, and our expectations for the remainder of the year, we are updating our 2014 annual guidance as follows:

Sales $695 - $705 million

GAAP Operating Income as a % of Sales ~11.0%

Adjusted Operating Income as a % of Sales ~13.0%

GAAP Diluted EPS $2.10 - $2.18

Adjusted Diluted EPS $2.32 - $2.38

Adjusted diluted EPS for 2014 is expected to consist of GAAP diluted EPS excluding items such as acquisition, consolidation, integration, asset disposition/write-down charges, and investment gains totaling approximately $8 million to $11 million. The after tax impact of these adjustments is estimated to be between $5 million to $7.5 million or $0.19 to $0.29 per share.

### Our CEO’s View

In line with our expectations, we delivered a solid quarter while continuing to invest in our global growth strategy. Our top-line performance, with the exception of portable medical, reflects our investments in sales and marketing and was at or above market trends with our orthopaedics and vascular product lines again delivering strong growth. Our growth in adjusted diluted EPS demonstrates our commitment to continued profitability. During 2014, we announced several capacity realignments and acquired CCC Medical Devices. We also received CE Mark for our spinal cord stimulator - Algovita, and we remain on track with our active implantable medical device strategy. These initiatives will be key to helping us achieve our financial objectives. We remain focused on delivering 5% year over year revenue growth and returning two times that amount to the bottom line leveraging our deep customer relationships, the strength of our intellectual property and our culture of continuous improvement.

### Product Development

#### Greatbatch Medical

Our core business is well positioned because our OEM customers leverage our portfolio of intellectual property, and we continue to build a healthy pipeline of diverse medical technology opportunities. We continue to deepen our relationships with our OEM customers and continue to see an increased pace of product development opportunities. These product development opportunities, when combined with the investments we have made in our sales and marketing resources, are expected to allow us to continue to grow faster than our underlying markets. Some of the product development opportunities Greatbatch Medical is pursuing are as follows:

| Product Line | Product Development Opportunities |
| --- | --- |
| Cardiac/ Neuromodulation | Developing next generation technology programs including Gen 2 QHR battery, next generation filtered feedthroughs, and high voltage capacitors. |
| Orthopaedic | Developing single use instruments and a suite of reusable bone preparation instruments with an emphasis on increased efficacy and longer life. |
| Portable Medical | Developing wireless power solutions for the surgical tool marketplace. |
| Vascular | Developing introducer technologies to expand into new clinical markets, as well as line extensions for current introducer platforms to better serve existing clinical markets and customers. |
| EME | Developing wide range temperature battery packs. |

- 33 -

#### QiG

Through QiG, we can provide our Greatbatch Medical customers with complete medical device systems. This medical device strategy includes strategic equity investments and medical devices developed independently, as well as in conjunction with our OEM partners. While we do not intend to discuss each of these projects individually, we will discuss significant milestones as they occur.

Algovita, our spinal cord stimulator to treat chronic intractable pain of the trunk and/or limbs, was designed to target unmet clinical needs with a focus on safety and product differentiation for all user groups. This product was submitted for PMA to the FDA in December 2013, and in January 2014 documentation for European CE Mark was submitted to the notified body, TÜV SÜD America. CE Mark approval was received in June 2014. Our Algovita project remains on track along both the regulatory approval pathway and early commercialization planning in Europe.

QiG is in the early stages of development of two additional medical device systems, which are targeting approved and emerging indications. Based upon the technology acquired from NeuroNexus Technologies, Inc. (“NeuroNexus”), QiG is developing a platform of thin-film electrodes for neuromodulation leads, sub-systems and components. Additionally, as a result of our acquisition of CCC, QiG is now able to more broadly partner with medical device companies, leveraging Greatbatch Medicals core discrete technology, which will enhance our medical device innovation efforts.

### Cost Savings and Consolidation Initiatives

In 2014 and 2013, we recorded charges in Other Operating Expenses, Net related to various cost savings and consolidation initiatives. These initiatives were undertaken to improve our operational efficiencies and profitability and consist of our 2013 operating unit realignment, optimizing our orthopaedic facilities, and upgrading and expanding our manufacturing infrastructure to support our medical device strategy. When fully implemented, the operating unit realignment is expected to result in annual savings of approximately $7.0 to $7.7 million and the orthopaedic and medical device initiatives are expected to generate approximately $10 million to $15 million of annual cost savings and to increase our capacity in order to support our growth and the manufacturing of complete medical devices.

In the second quarter of 2014, we announced several initiatives to invest in capacity and capabilities and to better align our resources to meet our customers' needs and drive organic growth and profitability. This included transferring certain functions currently performed at our Plymouth, MN, Beaverton, OR and Raynham, MA facilities into new and existing facilities in Tijuana, Mexico. Additionally, we announced the establishment of a R&D hub in the Minneapolis/St. Paul, MN area for the Company's Global R&D QiG - Medical Device Systems team and a commercial operations hub at our global headquarters in Frisco, Texas. We believe these initiatives will generate over $20 million of annualized savings beginning in 2016 and a full benefit in 2017.

Additional information regarding the timing, cash flow impact and amount of future expenditures for these initiatives is set forth in Note 9 “Other Operating Expenses, Net” of the Notes to the Condensed Consolidated Financial Statements contained in Item 1 of this report. We continually evaluate our operating structure in order to maximize efficiencies and drive margin expansion. Future charges could be incurred if new consolidation and optimization initiatives are undertaken.

### Our Financial Results

We utilize a fifty-two, fifty-three week fiscal year ending on the Friday nearest December 31st. For 52-week years, each quarter contains 13 weeks. The third quarter and year-to-date periods of 2014 and 2013 ended on October 3, and September 27, respectively, and each contained 13 weeks and 39 weeks, respectively. The commentary that follows should be read in conjunction with our Condensed Consolidated Financial Statements and related notes and with the Management’s Discussion and Analysis of Financial Condition and Results of Operations contained in our Annual Report on Form 10-K for the fiscal year ended January 3, 2014.

The following table presents certain selected financial information derived from our Condensed Consolidated Financial Statements for the periods presented (dollars in thousands, except per share data):

| Sales: Greatbatch Medical | Three Months Ended Oct. 3, 2014 | Sept. 27, 2013 | Change $% |  | Nine Months Ended Oct. 3, 2014 | Sept. 27, 2013 | Change $% |  |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cardiac/Neuromodulation | $85,618 | $86,302 | $(684) | (1)% | $252,403 | $240,003 | $12,400 | 5% |
| Orthopaedic | 32,489 | 30,079 | 2,410 | 8% | 106,785 | 92,043 | 14,742 | 16% |
| Portable Medical | 17,199 | 19,320 | (2,121) | (11)% | 53,139 | 60,376 | (7,237) | (12)% |
| Vascular | 14,903 | 12,279 | 2,624 | 21% | 43,210 | 35,152 | 8,058 | 23% |
| Energy, Military, Environmental | 19,016 | 19,072 | (56) | —% | 58,499 | 57,594 | 905 | 2% |
| Total Greatbatch Medical | 169,225 | 167,052 | 2,173 | 1% | 514,036 | 485,168 | 28,868 | 6% |
| QiG | 2,474 | 678 | 1,796 | 265% | 4,025 | 2,158 | 1,867 | 87% |
| Total sales | 171,699 | 167,730 | 3,969 | 2% | 518,061 | 487,326 | 30,735 | 6% |
| Cost of sales | 113,581 | 111,853 | 1,728 | 2% | 343,877 | 325,398 | 18,479 | 6% |
| Gross profit | 58,118 | 55,877 | 2,241 | 4% | 174,184 | 161,928 | 12,256 | 8% |
| Gross profit as a % of sales | 33.8% | 33.3% |  |  | 33.6% | 33.2% |  |  |
| Selling, general and administrative expenses (SG&A) | 22,121 | 21,569 | 552 | 3% | 65,753 | 63,909 | 1,844 | 3% |
| SG&A as a % of sales | 12.9% | 12.9% |  |  | 12.7% | 13.1% |  |  |
| Research, development and engineering costs, net (RD&E) | 13,638 | 13,806 | (168) | (1)% | 39,962 | 38,983 | 979 | 3% |
| RD&E as a % of sales | 7.9% | 8.2% |  |  | 7.7% | 8.0% |  |  |
| Other operating expenses, net | 6,176 | 3,500 | 2,676 | 76% | 10,223 | 10,560 | (337) | (3)% |
| Operating income | 16,183 | 17,002 | (819) | (5)% | 58,246 | 48,476 | 9,770 | 20% |
| Operating margin | 9.4% | 10.1% |  |  | 11.2% | 9.9% |  |  |
| Interest expense | 1,051 | 1,515 | (464) | (31)% | 3,208 | 9,948 | (6,740) | (68)% |
| Other (income) expense, net | (3,768) | (57) | (3,711) | NA | (4,055) | 907 | (4,962) | NA |
| Provision for income taxes | 4,888 | 4,473 | 415 | 9% | 17,811 | 11,135 | 6,676 | 60% |
| Effective tax rate | 25.9% | 28.8% |  |  | 30.1% | 29.6% |  |  |
| Net income | $14,012 | $11,071 | $2,941 | 27% | $41,282 | $26,486 | $14,796 | 56% |
| Net margin | 8.2% | 6.6% |  |  | 8.0% | 5.4% |  |  |
| Diluted earnings per share | $0.54 | $0.44 | $0.10 | 23% | $1.60 | $1.06 | $0.54 | 51% |

### Greatbatch Medical Sales

Total Greatbatch Medical sales for the third quarter of 2014 increased 1% in comparison to the prior year period and 6% for the first nine months of 2014. The most significant contributors to these variances were as follows:

Cardiac and neuromodulation sales for the third quarter of 2014 remained consistent with the prior year as new sales opportunities with existing customers offset the end of life impact for two legacy products. For the first nine months of 2014, cardiac and neuromodulation sales increased 5% due to the timing of customer product launches and inventory replenishments. Going forward, we expect growth in our cardiac and neuromodulation product line will continue to be negatively impacted by the end of life of two legacy products, which we expect will be mitigated by continued acceleration of recently launched products, as well as current and projected product development opportunities from our cardiac and neuromodulation customers. We continue to believe we are positioned to grow this category faster than the overall market growth although, when measured quarter over quarter, there will be some variation in our performance.

Orthopaedic sales for the third quarter and first nine months of 2014 increased 8% and 16%, respectively, in comparison to the prior year periods. Foreign currency exchange rate fluctuations did not materially impact orthopaedic sales for the third quarter of 2014 but increased sales by approximately $2.5 million for the year-to-date period in comparison to the prior year. On an organic constant currency basis, our orthopaedic product line sales increased 8% and 13% in comparison to the prior year third quarter and year-to-date periods, respectively. These increases were a result of increased implant and instrument sales primarily due to our sales force productivity, marketing efforts and market growth. For the year, we are forecasting low double digit growth in orthopaedics, excluding the impact of foreign currency exchange rate fluctuations, which we expect will reduce 2014 fourth quarter sales by approximately $1 million - $2 million due to the strengthening U.S. dollar versus the Euro.

Portable medical sales for the third quarter and first nine months of 2014 decreased 11% and 12%, respectively, in comparison to the prior year periods. We are refocusing our product line offerings in the portable medical space to products that have increased profitability and have discontinued or reduced volumes in certain of our lower margin products. The impact of this strategy is expected to begin to taper in the fourth quarter of 2014 but last through the first half of 2015. As part of our investment in capacity and capabilities and to better align our resources, during the second quarter of 2014, we announced plans to transfer our portable medical operations into a new facility located in Tijuana, Mexico. We remain optimistic about this product line and continue to see our pipeline of customer opportunities grow as we invest in new technologies to meet our customers’ needs and to expand our overall market opportunity.

Vascular sales for the third quarter and first nine months of 2014 increased 21% and 23%, respectively, in comparison to the prior year periods. These increases reflect the continued adoption of our medical device products and the relaunch of a vascular medical device near the end of 2013 which, as previously communicated, was voluntarily recalled in the fourth quarter of 2012. We anticipate continued strength in our vascular product line for the remainder of the year.

### QiG Sales

QiG revenue for the third quarter of 2014 includes sales from CCC, which we acquired on August 12, 2014 and contributed $1.6 million to sales during the quarter. CCC is an active implantable neuromodulation medical device systems developer and manufacturer that designs and produces a range of devices for some of the world's top neuromodulation medical device companies, including implantable pulse generators, programmer systems, battery chargers, patient wands and leads. Excluding the revenue acquired from CCC, QiG revenue increased 35% and 14% for the third quarter and year-to-date periods, respectively, in comparison to the prior year periods, due to increased adoption of our thin film electrode technology and new product launches.

G***ross Profit***

Changes to gross profit as a percentage of sales from the prior year were due to the following:

|  | Change From Prior Year Three Months | Nine Months |
| --- | ---: | ---: |
| Performance-based compensation(a) | 0.6% | 0.2% |
| Production efficiencies, volume and mix(b) | 1.0% | 1.4% |
| Impact of acquisition(c) | 0.1% | —% |
| Price(d) | (1.0)% | (1.0)% |
| Other | (0.2)% | (0.2)% |
| Total percentage point change to gross profit as a percentage of sales | 0.5% | 0.4% |

(a) Amount represents the change in performance-based compensation versus the prior year period and is recorded based upon the actual results achieved.

(b) Our gross profit percentage benefited from production efficiencies gained at our manufacturing facilities as a result of our various lean and supply chain initiatives, as well as higher production volumes due to increased sales. Additionally, our gross profit percentage benefited from an increase in mix of higher margin sales in comparison to the prior year.

(c) Amounts represent the impact to our gross profit percentage related to the acquisition of CCC in August 2014.

(d) Our gross profit percentage was negatively impacted by contractual price concessions to our larger OEM customers, which were given in exchange for long-term contracts and volume commitments.

Over the long-term, we expect to see gross margin improvements as we leverage our organic growth across our manufacturing footprint and realize the benefit of the various productivity improvement initiatives that are being implemented (see “Cost Savings and Consolidation Efforts” section of this Item). Additionally, we expect our gross margin to improve as more system and device level products are introduced, which typically earn a higher margin.

### SG&A Expenses

Changes to SG&A expenses from the prior year were due to the following (in thousands):

|  | Change From Prior Year Three Months | Nine Months |
| --- | ---: | ---: |
| Selling and marketing(a) | $1,060 | $3,510 |
| Performance-based compensation(b) | (1,045) | (1,245) |
| Legal fees(c) | 866 | 2,133 |
| G&A personnel costs(d) | 107 | (2,050) |
| Impact of acquisition(e) | 314 | 314 |
| Other | (750) | (818) |
| Net increase in SG&A | $552 | $1,844 |

(a) Amount represents the incremental SG&A expenses related to our strategic initiative to increase selling and marketing resources to drive core business growth and sustain a pipeline in order to achieve our 5% or better organic revenue growth performance goal.

(b) Amount represents the change in performance-based compensation versus the prior year and is recorded based upon the actual results achieved.

(c) Amount represents the increase in legal costs compared to the prior year and includes higher intellectual property related costs, as well as other corporate initiatives.

(d) Year-to-date amount represents lower G&A personnel costs incurred during 2014 in comparison to the prior year and is primarily a result of our various consolidation initiatives including our operating unit realignment that occurred during the second half of 2013. Quarter-to-date amounts are consistent with the prior year period.

(e) Amounts represent the incremental SG&A expenses related to the acquisition of CCC in August 2014.

### RD&E Expenses, Net

Net RD&E costs are comprised of the following (in thousands):

|  | Three Months Ended October 3, 2014 | September 27, 2013 | Nine Months Ended October 3, 2014 | September 27, 2013 |
| --- | ---: | ---: | ---: | ---: |
| Research, development, and engineering costs | $15,303 | $15,817 | $45,837 | $46,163 |
| Less cost reimbursements | (1,665) | (2,011) | (5,875) | (7,180) |
| Total RD&E, net | $13,638 | $13,806 | $39,962 | $38,983 |

Net RD&E for the 2014 third quarter decreased $0.2 million versus the comparable 2013 period and increased $1.0 million for the year-to-date period. For the third quarter and year-to-date periods we incurred lower DVT costs in connection with the development of our Algovita SCS system, which was submitted for PMA and CE Mark approval in December 2013 and January 2014, respectively. Third quarter 2014 DVT costs declined by $1.2 million compared to the 2013 third quarter and $3.1 million for the year-to-date period.

The 2014 third quarter and year-to-date periods also include higher costs incurred in connection with the development of our next generation cardiac products (i.e. batteries, capacitors, filtered feedthroughs), higher performance-based compensation, which was accrued based upon the achievement of certain Algovita milestones, and a higher rate of spend on other QiG medical device projects. In total, net medical device costs incurred by our QiG segment were $6.8 million for the third quarter 2014 ($18.9 million year-to-date), compared to $6.9 million for the respective 2013 period ($21.6 million year-to-date). QiG’s medical device technology investment is primarily focused on successfully commercializing Algovita, which continues to progress as planned, and selective opportunities that leverage the strengths of Greatbatch Medical to drive sustainable growth.

The decrease in customer costs reimbursements for the 2014 third quarter and year-to-date periods primarily relate to the timing of the achievement of milestones on customers cost reimbursement projects, as well as the expiration of certain government grants acquired from our acquisition of NeuroNexus in 2012.

### Other Operating Expenses, Net

Other operating expenses, net is comprised of the following (in thousands):

|  | Three Months Ended October 3, 2014 | September 27, 2013 | Nine Months Ended October 3, 2014 | September 27, 2013 |
| --- | ---: | ---: | ---: | ---: |
| 2014 investments in capacity and capabilities (a) | 2,787 | — | 5,005 | — |
| 2013 operating unit realignment(a) | (31) | 2,214 | 1,004 | 3,066 |
| Orthopaedic facility optimization costs(a) | 996 | 1,420 | 1,032 | 6,723 |
| Medical device facility optimization(a) | — | 52 | 11 | 282 |
| ERP system upgrade (income) costs(a) | — | (121) | (82) | 264 |
| Acquisition and integration (income) costs(b) | 133 | (522) | (248) | (340) |
| Asset dispositions, severance and other(c) | 2,291 | 457 | 3,501 | 565 |
| Total other operating expenses, net | $6,176 | $3,500 | $10,223 | $10,560 |

(a) Refer to “Cost Savings and Consolidation Initiatives” section of this Item and Note 9 “Other Operating Expenses, Net” of the Notes to the Condensed Consolidated Financial Statements contained in Item 1 of this report for disclosures related to the timing and level of remaining expenditures for these initiatives.

(b) During 2014 and 2013, we recognized (income) costs related to the integration of Micro Power Electronics, Inc., NeuroNexus, and CCC. These expenses (income) were primarily for retention bonuses, travel costs in connection with integration efforts, training, severance, and the change in fair value of the contingent consideration recorded in connection with the NeuroNexus acquisition. Refer to Note 14 “Fair Value Measurements” of the Notes to the Condensed Consolidated Financial Statements contained in Item 1 of this report for disclosures related to the change in fair value of the contingent consideration.

(c) During 2014 and 2013, we recorded charges in connection with various asset disposals and write-downs. During the third quarter of 2014, we also incurred $0.8 million of expense related to the separation of the Company's Senior Vice President, Human Resources. During the first three quarters of 2014, the Company recorded charges in connection with its business reorganization to align its contract manufacturing operations, which is expected to product tax savings over the long-term. Costs incurred primarily relate to consulting and IT development, which are expected to be completed by the end of 2014.

Other operating expenses, net is expected to be approximately $12 million to $15 million for 2014.

### Interest Expense

Interest expense for the third quarter and first nine months of 2014 decreased $0.5 million and $6.7 million, respectively, in comparison to the prior year periods. This decrease was primarily due to the repayment of our convertible subordinated notes during the first quarter of 2013. Additionally, interest expense was lower for the 2014 periods in comparison to 2013 due to lower outstanding Credit Facility balances, as well as lower interest rates paid on outstanding debt.

### Other (Income) Expense, Net

Other expense, net decreased $3.7 million and $5.0 million, respectively, for the 2014 third quarter and year-to-date periods in comparison to 2013. During the third quarter of 2014, we sold one of our cost method investments, which resulted in a pre-tax gain of $3.2 million. Additionally during the third quarter of 2014, we recognized $0.7 million of foreign currency exchange gains due to the strengthening of the U.S. dollar relative to the Euro. The 2014 year-to-date decrease in other expense, net is primarily due to $3.9 million of income realized on our cost and equity method investments and $0.4 million of income related to foreign currency exchange rate fluctuations. We generally do not expect foreign currency exchange rate fluctuations to have a material impact on our financial results.

### Provision for Income Taxes

The 2014 third quarter and year-to-date GAAP effective tax rate was 25.9% and 30.1%, respectively, compared to 28.8% and 29.6%, respectively, for the same period of 2013. The changes in the GAAP effective tax rate between the 2014 third quarter and year-to-date periods in comparison to the same periods of 2013 were primarily due to the timing of the Federal R&D tax credit, as well as the 2014 periods having higher income in lower tax rate jurisdictions. The Federal R&D tax credit expired at the end of 2013 and has not yet been extended for 2014. Additionally, we recognized the full year 2012 R&D tax credit in the first quarter of 2013 as the credit was reinstated, retroactive to the beginning of 2012, in that period.

We currently expect our 2014 annual GAAP and adjusted effective tax rate to each be in the range of 30% to 32%. This current expected GAAP effective tax rate for 2014 does not include the benefit of the U.S. Federal R&D tax credit. If reinstated, our 2014 GAAP effective tax rate could be lowered to 28% to 30%, but is already considered in our adjusted effective tax rate guidance.

We expect there to be continued volatility of this effective tax rate due to several factors, including changes in the mix of pre-tax income and the jurisdictions to which it relates, changes in tax laws and foreign tax holidays, business reorganizations, settlements with taxing authorities and foreign currency fluctuations. We currently have various tax planning initiatives in place that are aimed at reducing our effective tax rate over the long-term.

### Government Regulation

The Patient Protection and Affordable Care Act and the Health Care and Education Affordability Reconciliation Act (collectively “Health Care Reform”) legislated broad-based changes to the U.S. healthcare system that could significantly impact our business operations and financial results, including higher or lower revenue, as well as higher employee medical costs and taxes. Health Care Reform imposes significant new taxes on medical device OEMs, which will result in a significant increase in the tax burden on our industry and which could have a material negative impact on our financial condition, results of operations and our cash flows. Other elements of Health Care Reform such as comparative effectiveness research, an independent payment advisory board, payment system reforms including shared savings pilots and other provisions could meaningfully change the way healthcare is developed and delivered, and may materially impact numerous aspects of our business, results of operations and financial condition. Many significant parts of Health Care Reform will be phased in over the next several years and require further guidance and clarification in the form of regulations. The medical device tax, which was effective in 2013, increased our cost of sales by $0.2 million and $0.6 million for the 2014 third quarter and year-to-date periods, respectively.

In the first quarter of 2014, we initiated a voluntary field corrective action for all Standard Offset Cup Impactors after an internal review determined that the sterilization recommendation in the Instructions For Use for the product did not meet requirements for sterility assurance, which has the potential to result in surgical infection. We have validated two sterilization parameters that meet acceptable sterility assurance levels and provided them to affected customers. We have informed the FDA and other government agencies of this action, which impacts all Standard Offset Cup Impactors manufactured and distributed from 2004 to 2013. Greatbatch has received three complaints possibly related to this issue, however no adverse events have been reported. Future customer complaints or negative regulatory actions regarding this product or any of our products could harm our operating results or financial condition.

### Liquidity and Capital Resources

*(Dollars in thousands)*

|  | As of October 3, 2014 | January 3, 2014 |
| --- | ---: | ---: |
| Cash and cash equivalents | $61,582 | $35,465 |
| Working capital | $236,976 | $190,731 |
| Current ratio | 3.63 | 3.08 |

The increase in cash and cash equivalents and working capital from the end of 2013 was primarily due to our operating income, which generated $54.7 million in net cash provided by operating activities partially offset by the $15.8 million net cash paid for the CCC acquisition and $16.0 million of capital expenditures. Additionally, working capital balances increased from the end of 2013, primarily accounts receivable and inventory, due to our growth in sales and expected sales as well as our acquisition of CCC. Of the $61.6 million of cash and cash equivalents on hand as of October 3, 2014, $10.3 million is being held at our foreign subsidiaries and is considered permanently reinvested.

***Credit Facility –*** We have a credit facility (the “Credit Facility”), which consists of a $300 million revolving line of credit (the “Revolving Credit Facility”), a $200 million term loan (the “Term Loan”), a $15 million letter of credit subfacility, and a $15 million swingline subfacility. The Revolving Credit Facility can be increased by $200 million upon our request and approval by the lenders. The Revolving Credit Facility has a maturity date of September 20, 2018, which may be extended to September 20, 2019 upon notice by us and subject to certain conditions. The principal of the Term Loan is payable in quarterly installments as specified in the Credit Facility until its maturity date of September 20, 2019 when the unpaid balance is due in full.

The Credit Facility is supported by a consortium of fifteen banks with no bank controlling more than 18% of the facility. As of October 3, 2014, each bank supporting 98% of the Credit Facility has an S&P credit rating of at least BBB or better, which is considered investment grade. The bank which supports the remaining 2% of the Credit Facility is not currently being rated.

The Credit Facility requires us to maintain a rolling four quarter ratio of adjusted EBITDA to interest expense of at least 3.0 to 1.0. For the twelve month period ended October 3, 2014, our ratio of adjusted EBITDA to interest expense, calculated in accordance with our Credit Facility, was 31.0 to 1.0, well above the required limit. The Credit Facility also requires us to maintain a total leverage ratio of not greater than 4.5 to 1.0 and not greater than 4.25 to 1.0 after January 2, 2016. As of October 3, 2014, our total leverage ratio, calculated in accordance with our Credit Facility, was 1.4 to 1.0, well below the required limit.

See Note 6 “Debt” of the Notes to the Condensed Consolidated Financial Statements contained in Item 1 of this report for a more detailed description of the Credit Facility.

As of October 3, 2014, we had $300 million of borrowing capacity available under the Credit Facility. This amount may vary from period to period based upon our debt and EBITDA levels, which impacts the covenant calculations discussed above. We believe that our cash flow from operations and available borrowing capacity under the Credit Facility provide adequate liquidity to meet our short- and long-term funding needs.

***Operating activities –*** Cash provided by operations for the first nine months of 2014 were $54.7 million versus $16.1 million for the comparable 2013 period. This increase was primarily due to a higher level of operating income in 2014 as compared to 2013, as well as improved working capital management. Additionally, for the first nine months of 2013, the Company paid $19.6 million of estimated tax payments in connection with the retirement of our convertible subordinated notes.

***Investing activities –*** Net cash used in investing activities for the first nine months of 2014 were $24.9 million compared to $13.8 million in the comparable 2013 period. 2014 investing activities include $15.8 million of net cash used for the acquisition of CCC during the third quarter of 2014, as well as $16.0 million of cash used for the purchase of property, plant and equipment. These transactions were partially offset by a $2.7 million contingent payment received in 2014 in connection with the sale of certain non-core Swiss orthopaedic product lines, which closed during the first quarter of 2013, as well as $4.3 million of proceeds received during the third quarter of 2014 from the sale of a cost method investment. Our current expectation is that capital spending for the full year of 2014 will be in the range of $20 million to $25 million, of which approximately half is discretionary in nature. We anticipate that cash on hand, cash flow from operations and available borrowing capacity under our Credit Facility will be sufficient to fund these capital expenditures. As part of our growth strategy, we have and will continue to consider targeted and opportunistic acquisitions.

***Financing activities –*** Net cash used in financing activities for the first nine months of 2014 were $2.9 million compared to $17.6 million in the comparable 2013 period. This cash outflow is the result of $7.5 million of principal payments on long-term debt partially offset by $5.7 million of cash received from the exercise of stock options during the first nine months of 2014.

***Capital Structure –*** As of October 3, 2014, our capital structure consisted of $190 million of debt under our Term Loan and 24.9 million shares of common stock outstanding. Additionally, we had $61.6 million in cash and cash equivalents. If necessary, we currently have access to $300 million under our Revolving Credit Facility and are authorized to issue 100 million shares of common stock and 100 million shares of preferred stock. We believe that, if needed, we can access public markets to raise additional capital. We believe that our capital structure provides adequate funding to meet our growth objectives. We continuously evaluate our capital structure, including our Credit Facility, as it relates to our anticipated long-term funding needs. Changes to our capital structure may occur as a result of this analysis, or changes in market conditions.

### Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements within the meaning of Item 303(a)(4) of Regulation S-K.

### Impact of Recently Issued Accounting Standards

In the normal course of business, we evaluate all new accounting pronouncements issued by the Financial Accounting Standards Board (“FASB”), Securities and Exchange Commission (“SEC”), Emerging Issues Task Force (“EITF”), American Institute of Certified Public Accountants (“AICPA”) or other authoritative accounting body to determine the potential impact they may have on our Condensed Consolidated Financial Statements. Based upon this review, except as noted in Note 16 “Impact of Recently Issued Accounting Standards” of the Notes to the Condensed Consolidated Financial Statements contained in Item 1 of this report, we do not expect any of the recently issued accounting pronouncements, which have not already been adopted, to have a material impact on our Condensed Consolidated Financial Statements.

### Contractual Obligations

A table of our contractual obligations as of January 3, 2014 was included in Item 7, “Management's Discussion and Analysis of Financial Condition and Results of Operations” of our Annual Report on Form 10-K for the fiscal year ended January 3, 2014. There have been no significant changes to our contractual obligations during the nine months ended October 3, 2014. See Note 11 “Commitments and Contingencies” of the Notes to the Condensed Consolidated Financial Statements contained in Item 1 of this report for further discussion on our contractual obligations.

### Forward-Looking Statements

Some of the statements contained in this report and other written and oral statements made from time to time by us and our representatives are not statements of historical or current fact. As such, they are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We have based these forward-looking statements on our current expectations, which are subject to known and unknown risks, uncertainties and assumptions. They include statements relating to:

- future sales, expenses and profitability;
- the future development and expected growth of our business and industry;
- our ability to successfully execute our business model and our business strategy;
- our ability to identify trends within our markets and to offer products and services that meet the changing needs of those markets; and
- projected capital expenditures.

You can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” or “continue,” or variations or the negative of these terms or other comparable terminology. These statements are only predictions. Actual events or results may differ materially from those suggested by these forward-looking statements. In evaluating these statements and our prospects generally, you should carefully consider the factors set forth below. All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by these cautionary factors and to others contained throughout this report. We are under no duty to update any of the forward-looking statements after the date of this report or to conform these statements to actual results.

Although it is not possible to create a comprehensive list of all factors that may cause actual results to differ from the results expressed or implied by our forward-looking statements or that may affect our future results, some of these factors include the following: our dependence upon a limited number of customers; customer ordering patterns; product obsolescence; our inability to market current or future products; pricing pressure from customers; our ability to timely and successfully implement cost reduction and plant consolidation initiatives; our reliance on third party suppliers for raw materials, products and subcomponents; fluctuating operating results; our inability to maintain high quality standards for our products; challenges to our intellectual property rights; product liability claims; product field actions or recalls; our inability to successfully consummate and integrate acquisitions and to realize synergies and to operate these acquired businesses in accordance with expectations; our unsuccessful expansion into new markets; our failure to develop new products including system and device products; our inability to obtain licenses to key technology; regulatory changes, including Healthcare Reform, or consolidation in the healthcare industry; global economic factors including currency exchange rates and interest rates; the resolution of various legal actions brought against the Company; and other risks and uncertainties that arise from time to time as described in the Company’s Annual Report on Form 10-K and other periodic filings with the SEC.

## Market risk

As filed, 5,655 characters.

***Foreign Currency –*** We have foreign operations in France, Mexico, Switzerland and Uruguay, which expose the Company to foreign currency exchange rate fluctuations due to transactions denominated in Euros, Mexican pesos, Swiss francs and Uruguayan pesos, respectively. We continuously evaluate our foreign currency risk and will take action from time to time in order to best mitigate these risks, which includes the use of various derivative instruments such as forward currency exchange rate contracts. A hypothetical 10% change in the value of the U.S. dollar in relation to our most significant foreign currency exposures would have had an impact of approximately $7 million on our annual sales. This amount is not indicative of the hypothetical net earnings impact due to partially offsetting impacts on cost of sales and operating expenses in those currencies. We estimate that foreign currency exchange rate fluctuations during the nine months ended October 3, 2014 increased sales in comparison to the 2013 period by approximately $2.5 million.

In 2013, we entered into two forward contracts to purchase 8.4 million and 7.0 million Mexican pesos per month beginning in January 2014 through December 2014 at an exchange rate of $0.0767 and $0.0752 per peso, respectively. These contracts were entered into in order to hedge the risk of peso-denominated payments associated with a portion of the operations at our Tijuana, Mexico facility for 2014 and are being accounted for as cash flow hedges. As of October 3, 2014, these contracts had a negative fair value of $0.1 million. The amount recorded as a reduction of Cost of Sales during the nine months ended October 3, 2014 and September 27, 2013 related to our forward contracts was $0.2 million and $0.9 million, respectively. No portion of the change in fair value of our foreign currency exchange rate contracts during the nine months ended October 3, 2014 or September 27, 2013 was considered ineffective.

We translate all assets and liabilities of our foreign operations, where the U.S. dollar is not the functional currency, at the period-end exchange rate and translate sales and expenses at the average exchange rates in effect during the period. The net effect of these translation adjustments is recorded in the Condensed Consolidated Financial Statements as Comprehensive

Income. The translation adjustment for the first nine months of 2014 was a loss of $2.4 million and for the first nine months of 2013 was a gain of $1.1 million. Translation adjustments are not adjusted for income taxes as they relate to permanent investments in our foreign subsidiaries. Net foreign currency transaction gains and losses included in Other (Income) Expense, Net amounted to a gain of $0.4 million and $0.02 million for the first nine months of 2014 and 2013, respectively. A hypothetical 10% change in the value of the U.S. dollar in relation to our most significant foreign currency net assets would have had an impact of approximately $2 million on our foreign net assets as of October 3, 2014.

***Interest Rates –*** Interest rates on our Credit Facility reset, at our option, based upon the prime rate or LIBOR rate, thus subjecting us to interest rate risk. To help offset this risk, from time to time, we enter into receive floating-pay fixed interest rate swaps indexed to the same applicable index rate as the debt it is hedging. In October 2012, we entered into a three-year $150 million interest rate swap, which amortizes $50 million per year beginning in 2014 and became effective during the first quarter of 2013. Under terms of the contract, we receive a floating interest rate indexed to the one-month LIBOR rate and pay a fixed interest rate of 0.573%. This swap was entered into in order to hedge against potential changes in cash flows on our outstanding variable-rate debt, which is also indexed to the one-month LIBOR rate. The receive variable leg of the interest rate swap and the variable rate paid on the debt is expected to have the same rate of interest, excluding the credit spread, and reset and pay interest on the same dates. This swap is accounted for as a cash flow hedge.

As of October 3, 2014, we had $190 million outstanding under the Term Loan, of which $100 million is currently being hedged. See Note 6 “Debt” of the Notes to Condensed Consolidated Financial Statements in Item 1 of this report for additional information about our outstanding debt. A hypothetical one percentage point (100 basis points) change in the LIBOR rate on the $90 million of unhedged floating rate debt outstanding at October 3, 2014 would have an impact of approximately $0.9 million on our interest expense.

On November 3, 2014, we entered into an additional interest rate swap in order to hedge against potential changes in cash flows on the outstanding borrowings on our Credit Facility. The first $45 million of notional amount of the swap is effective February 20, 2015 and the second $45 million of notional amount is effective February 22, 2016. The notional amount of the swap amortizes $10 million per year beginning on February 21, 2017, with the remaining settled on the termination date of the swap agreement on September 20, 2019. Under the terms of the swap agreement we will pay a fixed interest rate of 1.921% and receive a floating interest rate equal to the one-month LIBOR rate. The variable rate received on the interest rate swaps and the variable rate paid on the Credit Facility will have the same rate of interest, excluding the credit spread, and will reset and pay interest on the same date. The swap will be accounted for as a cash flow hedge.

## Controls and procedures

As filed, 2,476 characters.

a. Evaluation of Disclosure Controls and Procedures.

Our management, including the principal executive officer and principal financial officer, evaluated our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934) related to the recording, processing, summarization and reporting of information in our reports that we file with the SEC as of October 3, 2014. These disclosure controls and procedures have been designed to provide reasonable assurance that material information relating to us, including our subsidiaries, is made known to our management, including these officers, by other of our employees, and that this information is recorded, processed, summarized, evaluated and reported, as applicable, within the time periods specified in the SEC’s rules and forms. Based on their evaluation, as of October 3, 2014, our principal executive officer and principal financial officer have concluded that our disclosure controls and procedures are effective.

b. Changes in Internal Control Over Financial Reporting.

We completed the acquisition of Centro de Construcción de Cardioestimuladores del Uruguay (“CCC”) on August 12, 2014. We believe that the internal controls and procedures of CCC are reasonably likely to materially affect our internal control over financial reporting. We are currently in the process of incorporating the internal controls and procedures of CCC into our existing internal controls over financial reporting.

The Company continues to extend its Section 404 compliance program under the Sarbanes-Oxley Act of 2002 (the “Act”) and the applicable rules and regulations under such Act to include CCC. The Company expects to exclude the acquisition of CCC from management’s assessment of the effectiveness of internal control over financial reporting for fiscal year 2014, as permitted by the guidance issued by the Office of the Chief Accountant of the SEC. The Company expects to report on its assessment of the internal controls of its combined operations within the time period provided by the Act and the applicable SEC rules and regulations concerning business combinations.

There have been no changes in our internal control over financial reporting that occurred during our last fiscal quarter to which this Quarterly Report on Form 10-Q relates that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

## Risk factors

As filed, 171 characters.

There have been no material changes from the Company’s risk factors as previously disclosed in the Company’s Annual Report on Form 10-K for the year ended January 3, 2014.

Filed Nov 12, 2014.
Source: SEC EDGAR, the filing index for accession 0001114483-14-000032. Last ingested by Listed: Nov 11, 2026, 00:08 ET. No prices; not investment advice.
